Dr. Reddy's Laboratories (NYS: RDY) reported earnings on Feb. 14. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q3), Dr. Reddy's Laboratories missed estimates on revenues and missed estimates on earnings per share.
Compared to the prior-year quarter, revenue was unchanged and GAAP earnings per share dropped significantly.
Margins shrank across the board.
Dr. Reddy's Laboratories reported revenue of $522.1 million. The 14 analysts polled by S&P Capital IQ looked for revenue of $545.7 million on the same basis. GAAP reported sales were the same as the prior-year quarter's.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.40. The two earnings estimates compiled by S&P Capital IQ predicted $0.53 per share. GAAP EPS of $0.40 for Q3 were 30% lower than the prior-year quarter's $0.57 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 52.7%, 720 basis points worse than the prior-year quarter. Operating margin was 16.5%, 1,070 basis points worse than the prior-year quarter. Net margin was 13.2%, 530 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $595.5 million. On the bottom line, the average EPS estimate is $0.60.
Next year's average estimate for revenue is $2.12 billion. The average EPS estimate is $1.89.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 483 members out of 509 rating the stock outperform, and 26 members rating it underperform. Among 112 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 109 give Dr. Reddy's Laboratories a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Dr. Reddy's Laboratories is outperform, with an average price target of $35.13.
Add Dr. Reddy's Laboratories to My Watchlist.
The article Dr. Reddy's Laboratories Misses on the Top and Bottom Lines originally appeared on Fool.com.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.